Ambroxol is under clinical development by Belrose Pharma and currently in Phase II for Gaucher Disease Type I. According to GlobalData, Phase II drugs for Gaucher Disease Type I have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ambroxol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ambroxol overview
Ambroxol (BEL-0218) is under development for the treatment of Parkinson's disease and Gaucher Disease Type I. The drug candidate is administered through oral route formulated as tablet. It is a small molecule pharmacological chaperone. Ambroxol binds to beta-glucocerebrosidase (Gcase) enzyme. It is based on hydrogen/deuterium exchange platform technology (H/D-Ex). It was also under development for the treatment of Gaucher Disease Type III.
Belrose Pharma overview
Belrose Pharma is a pharmaceutical company that develops clinical stage biopharma PEG-based formulations for cancer and rare diseases. Belrose Pharma is headquartered in Princeton, New Jersey, the US.
For a complete picture of Ambroxol’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
